Gene:
CDKN2B
cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  CDK4I; INK4B; MTS2; P15; TP15; p15INK4b
PharmGKB Accession Id: PA26321

Details

Cytogenetic Location: chr9 : p21.3 - p21.3
GP mRNA Boundary: chr9 : 22002902 - 22009312
GP Gene Boundary: chr9 : 21999902 - 22019312
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. cell cycle: g1/s check point - (BioCarta via Pathway Interaction Database)
  2. cyclins and cell cycle regulation - (BioCarta via Pathway Interaction Database)
  3. Regulation of nuclear SMAD2/3 signaling - (Pathway Interaction Database NCI-Nature Curated)

Publications related to CDKN2B: 7

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nature genetics. 2012. Manning Alisa K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Key pathways are frequently mutated in high risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011. Zhang Jinghui, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes. 2008. Moore Allan F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mutations in TOPORS cause autosomal dominant retinitis pigmentosa with perivascular retinal pigment epithelium atrophy. American journal of human genetics. 2007. Chakarova Christina F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science (New York, N.Y.). 2007. Scott Laura J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (New York, N.Y.). 2007. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science (New York, N.Y.). 2007. Zeggini Eleftheria, et al. PubMed

LinkOuts

Entrez Gene:
1030
OMIM:
600431
UCSC Genome Browser:
NM_004936
RefSeq RNA:
NM_004936
NM_078487
RefSeq Protein:
NP_004927
NP_511042
RefSeq DNA:
AC_000052
AC_000141
NC_000009
NG_023297
NT_008413
NW_001839149
NW_924062
UniProtKB:
O15125_HUMAN (O15125)
CDN2B_HUMAN (P42772)
Ensembl:
ENSG00000147883
GenAtlas:
CDKN2B
GeneCard:
CDKN2B
MutDB:
CDKN2B
ALFRED:
LO037921W
HuGE:
CDKN2B
Comparative Toxicogenomics Database:
1030
ModBase:
P42772
HumanCyc Gene:
HS07479
HGNC:
1788

Common Searches